Literature DB >> 17357475

Comparison of properties of tumor necrosis factor-alpha converting enzyme (TACE) and some matrix metalloproteases (MMPs) in catalytic domains.

Yunbin Zhao1, Wenfang Feng, Yuzhen Yang, Lunjiang Ling, Runsheng Chen.   

Abstract

The crystal structural data of TACE, MMP-1, MMP-2, MMP-3 and MMP-9 were obtained from PDB database, and then their catalytic domains' properties including conformation, molecular surface hydrophobicity and electrostatic potential were analyzed and compared by using Insight II molecular modeling software. It was found that the conformation and molecular surface hydrophobicity of catalytic domains of TACE and MMPs were not obviously different, but the molecular surface electrostatic potential of catalytic domain of TACE and MMPs had obvious differences. The findings are helpful in the Rational Drug Design of TACE selective inhibitor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17357475     DOI: 10.1007/s11596-006-0601-9

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  11 in total

1.  New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors.

Authors: 
Journal:  Oncologist       Date:  1998

Review 2.  Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha.

Authors:  R C Newton; C P Decicco
Journal:  J Med Chem       Date:  1999-07-01       Impact factor: 7.446

Review 3.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling.

Authors:  J F Woessner
Journal:  FASEB J       Date:  1991-05       Impact factor: 5.191

4.  A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.

Authors:  R A Black; C T Rauch; C J Kozlosky; J J Peschon; J L Slack; M F Wolfson; B J Castner; K L Stocking; P Reddy; S Srinivasan; N Nelson; N Boiani; K A Schooley; M Gerhart; R Davis; J N Fitzner; R S Johnson; R J Paxton; C J March; D P Cerretti
Journal:  Nature       Date:  1997-02-20       Impact factor: 49.962

5.  1H, 13C and 15N resonance assignments for a truncated and inhibited catalytic domain of matrix metalloproteinase-2.

Authors:  Y Feng; J Likos; L Zhu; H Woodward; J McDonald; A Stevens; S Howard; D Welsch
Journal:  J Biomol NMR       Date:  2000-05       Impact factor: 2.835

6.  Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors.

Authors:  B Lovejoy; A R Welch; S Carr; C Luong; C Broka; R T Hendricks; J A Campbell; K A Walker; R Martin; H Van Wart; M F Browner
Journal:  Nat Struct Biol       Date:  1999-03

Review 7.  Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis.

Authors:  K M Murray; S L Dahl
Journal:  Ann Pharmacother       Date:  1997-11       Impact factor: 3.154

8.  Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme.

Authors:  K Maskos; C Fernandez-Catalan; R Huber; G P Bourenkov; H Bartunik; G A Ellestad; P Reddy; M F Wolfson; C T Rauch; B J Castner; R Davis; H R Clarke; M Petersen; J N Fitzner; D P Cerretti; C J March; R J Paxton; R A Black; W Bode
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

9.  Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.

Authors:  S V Onrust; H M Lamb
Journal:  BioDrugs       Date:  1998-11       Impact factor: 5.807

10.  Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor.

Authors:  Siân Rowsell; Paul Hawtin; Claire A Minshull; Holly Jepson; Sarah M V Brockbank; Derek G Barratt; Anthony M Slater; William L McPheat; David Waterson; Adriano M Henney; Richard A Pauptit
Journal:  J Mol Biol       Date:  2002-05-24       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.